Nicotine therapeutic benefits: Difference between revisions

Line 1,131:

**Citation: Tizabi Y, Getachew B, Aschner M. Butyrate protects and synergizes with nicotine against iron- and manganese-induced toxicities in cell culture: Implications for neurodegenerative diseases. Res Sq [Preprint]. 2023 Oct 5:rs.3.rs-3389904. doi: 10.21203/rs.3.rs-3389904/v1. Update in: Neurotox Res. 2023 Dec 14;42(1):3. doi: 10.1007/s12640-023-00682-z. PMID: 37886507; PMCID: PMC10602090.

***Acknowledgement: Supported in part by: NIH/NIAAA R03 AA022479 and NIH/NIGMS (2 SO6 GM08016‐39) (YT), and NIEHS R01ES10563 and R01ES07331 (MA).

===2021 [https://www.nature.com/articles/s41598-021-88910-4 Nicotine suppresses Parkinson’s disease like phenotypes induced by Synphilin-1 overexpression in Drosophila melanogaster by increasing tyrosine hydroxylase and dopamine levels]===

*Insect study

*In conclusion our data show that the PD model by expression of Sph-1 in dopaminergic neurons provides a good opportunity to study the early prodromal stages of PD, while also the late onset symptoms such as neurodegeneration and motor impairment in aged animals. On the other hand, working on this animal model has allowed us to advance on the therapeutic effects of nicotine treatment over several PD-linked features. The protective effect of nicotine appears to be specific for the genotype predisposed to develop a parkinsonian phenotype and provide a hint on the idea that nicotine treatment even in later stages of the disease could be beneficial to patients. Our findings provide new ideas that contribute to a better understanding on the mechanisms underlying the positive effects of nicotine in PD.

**Citation: Carvajal-Oliveros, A., Domínguez-Baleón, C., Zárate, R.V. et al. Nicotine suppresses Parkinson’s disease like phenotypes induced by Synphilin-1 overexpression in Drosophila melanogaster by increasing tyrosine hydroxylase and dopamine levels. Sci Rep 11, 9579 (2021). https://doi.org/10.1038/s41598-021-88910-4

***Acknowledgement: This work was supported by the CONACyT (Grant Number 255478) and by DGAPA-PAPIIT (Grant Number IN206517).

=== 2020: [https://n.neurology.org/content/94/20/e2132 Tobacco smoking and the risk of Parkinson disease A 65-year follow-up of 30,000 male British doctors] ===

@@ Line 1,131: / Line 1,131: @@
 **Citation: Tizabi Y, Getachew B, Aschner M. Butyrate protects and synergizes with nicotine against iron- and manganese-induced toxicities in cell culture: Implications for neurodegenerative diseases. Res Sq [Preprint]. 2023 Oct 5:rs.3.rs-3389904. doi: 10.21203/rs.3.rs-3389904/v1. Update in: Neurotox Res. 2023 Dec 14;42(1):3. doi: 10.1007/s12640-023-00682-z. PMID: 37886507; PMCID: PMC10602090.
 ***Acknowledgement: Supported in part by: NIH/NIAAA R03 AA022479 and NIH/NIGMS (2 SO6 GM08016‐39) (YT), and NIEHS R01ES10563 and R01ES07331 (MA).
+===2021 [https://www.nature.com/articles/s41598-021-88910-4 Nicotine suppresses Parkinson’s disease like phenotypes induced by Synphilin-1 overexpression in Drosophila melanogaster by increasing tyrosine hydroxylase and dopamine levels]===
+*Insect study
+*In conclusion our data show that the PD model by expression of Sph-1 in dopaminergic neurons provides a good opportunity to study the early prodromal stages of PD, while also the late onset symptoms such as neurodegeneration and motor impairment in aged animals. On the other hand, working on this animal model has allowed us to advance on the therapeutic effects of nicotine treatment over several PD-linked features. The protective effect of nicotine appears to be specific for the genotype predisposed to develop a parkinsonian phenotype and provide a hint on the idea that nicotine treatment even in later stages of the disease could be beneficial to patients. Our findings provide new ideas that contribute to a better understanding on the mechanisms underlying the positive effects of nicotine in PD.
+**Citation: Carvajal-Oliveros, A., Domínguez-Baleón, C., Zárate, R.V. et al. Nicotine suppresses Parkinson’s disease like phenotypes induced by Synphilin-1 overexpression in Drosophila melanogaster by increasing tyrosine hydroxylase and dopamine levels. Sci Rep 11, 9579 (2021). https://doi.org/10.1038/s41598-021-88910-4
+***Acknowledgement: This work was supported by the CONACyT (Grant Number 255478) and by DGAPA-PAPIIT (Grant Number IN206517).
 === 2020: [https://n.neurology.org/content/94/20/e2132 Tobacco smoking and the risk of Parkinson disease A 65-year follow-up of 30,000 male British doctors] ===